Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

Abstract Background The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-direc...

Full description

Bibliographic Details
Main Authors: Neil R. Parikh, Claudia Huiza, Jill S. Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P. Lee, Warren S. Inouye, Mark L. Jordan, Homayoon Sanati, Lida Jafari, Carol J. Bennett, Greg E. Gin, Amar U. Kishan, Robert E. Reiter, Michael Lewis, Ahmad Sadeghi, William J. Aronson, Isla P. Garraway, Matthew B. Rettig, Nicholas G. Nickols
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Oligometastases
Prostate cancer
Stereotactic body radiotherapy
Abiraterone
Apalutamide
Leuprolide
Online Access:http://link.springer.com/article/10.1186/s12885-019-5496-5

Internet

http://link.springer.com/article/10.1186/s12885-019-5496-5

Similar Items